Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

QRxPharma Ltd Announces Grant Of US Patent On Hybrid Opioids

Tuesday, 11 Jun 2013 08:17pm EDT 

QRxPharma Ltd announced that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent #8,461,171 (171 patent) titled 'Hybrid Opioid Compounds and Compositions', which expires in 2031. This patent covers a hybrid morphine-oxycodone molecule where these two different opioids are chemically linked. The ’171 patent covers the development of new chemical entities that have the potential to provide better pain relief and fewer side effects than their individual components. The Company has related patents pending both internationally and in the United States. 

Company Quote

-0.0030 -3.49%
11 Jul 2014